Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Nano-sized drug particles to expand HIV treatment further

Research at the University of Liverpool could benefit millions of HIV patients in developing countries through a nano-technology programme aimed at making drug treatment more effective.

Published
09 April 2014
From
Medical Xpress
Giving treatment to specific high-risk people may bring down HIV faster than distributing it equally

In a concentrated epidemic, HIV is mainly restricted to – or at least more common in – specific risk groups. In this situation, and if universal

Published
08 April 2014
By
Gus Cairns
Long-acting HIV drugs advanced to overcome adherence challenge

If it proves effective, long-acting antiretroviral therapy would set up a new paradigm of monthly or quarterly injectable therapy for some patients. Long-acting drug formulations could solve one of the thorniest problems in HIV management - adherence.

Published
08 April 2014
From
Nature Medicine
Better Late Than Never: Efavirenz Dose Optimization

After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

Published
03 April 2014
From
Treatment Action Group
Quality of life for people with HIV in the UK remains poor, despite treatment successes

Compared to the general population, people with HIV experienced lower HRQoL in all of the areas they were questioned about, but especially anxiety and depression. Being female, non-white, without children and having a lower level of education were associated with lower HRQoL. The negative effect of HIV on overall HRQoL was similar to heavy smoking.

Published
02 April 2014
From
British HIV Association
Viiv Healthcare licenses dolutegravir (Tivicay) to Medicines Patent Pool

The collaboration with MPP includes two distinct approaches to improve access for adults living with HIV in the developing world: first, a royalty-free voluntary licence in all least-developed, all low-income and all sub-Saharan African countries; second, for specific middle-income countries including India, ViiV Healthcare has established the first-ever MPP licence with a tiered royalty structure, where a small percentage of the sale price is paid based on the gross domestic product (GDP) of the specific country.

Published
02 April 2014
From
Viiv Healthcare press release
Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

"Darunavir is the most prescribed HIV protease inhibitor in the United States and we are excited to be taking this important step in our efforts to offer it with an alternative boosting agent in a fixed-dose combination tablet," said Johan van Hoof, M.D., Therapeutic Area Head, Infectious Diseases and Vaccines, Janssen.

Published
02 April 2014
From
Janssen press release
United Healthcare To Allow HIV/AIDS Patients to "Opt-Out" of Mail-Order Prescriptions

United Healthcare, the United States' largest health insurer, will allow patients with HIV or AIDS who have privacy or delivery concerns, or who have difficulty discussing their HIV medications over the phone, to obtain their medications from an in-network retail pharmacy rather than by mail order.

Published
01 April 2014
From
Consumer Watchdog
Standard HIV treatment achieves high concentrations in female genital tract and suppresses shedding of virus

Standard antiretroviral therapy containing tenofovir, FTC and atazanavir achieves high concentrations in the female genital tract and suppresses HIV replication throughout the menstrual cycle, US investigators report

Published
01 April 2014
By
Michael Carter
Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

The updated guidelines include recommendations for use of newer antiretroviral drugs, including those in new classes, such as CCR5 receptor antagonists and integrase inhibitors. The new guidelines provide additional recommendations regarding use of rifampin with antiretroviral therapy; these recommendations are critical in regions where rifabutin is unavailable.

Published
31 March 2014
From
Morbidity and Mortality Weekly Report

Filter by country